Spike Trimer Neutralizing Antibody (B.1.617.2, B.1.617.2.1, WT and B.1.1.7 Variants) (Clone hC-A11) (SARS-CoV-2)
101061
ApplicationsFunctional Assay, Neutralisation/Blocking
Product group Antibodies
TargetS
Overview
- SupplierBPS Bioscience
- Product NameSpike Trimer Neutralizing Antibody (B.1.617.2, B.1.617.2.1, WT and B.1.1.7 Variants) (Clone hC-A11) (SARS-CoV-2)
- Delivery Days Customer7
- Antibody SpecificityThe antibody neutralizes the wildtype, B.1.1.7 (Alpha), B.1.617.2 (Delta) and B.1.617.2.1 (Delta Plus) variants of SARS-CoV-2 Spike RBD and Trimeric proteins
- ApplicationsFunctional Assay, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDhC-A11
- Gene ID43740568
- Target nameS
- Target descriptionsurface glycoprotein
- Target synonymsGU280_gp02; spike glycoprotein; surface glycoprotein
- HostHuman
- IsotypeIgG1
- Protein IDP0DTC2
- Protein NameSpike glycoprotein
- Scientific DescriptionThis antibody is a humanized monoclonal antibody which recognizes SARS-CoV-2 spike RBD and the full-length spike proteins in the native trimeric conformation. This antibody is derived from rabbit monoclonal C-A11 neutralizing antibody (BPS Bioscience, #101024). It cross-reacts with the wildtype as well as the B.1.617.2 (Delta Variant), B.1.617.2.1 (Delta PLUS Variant), B.1.1.7 (Alpha Variant) RBDs and spike protein trimers [See Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Sike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (available for purchase).
- Storage Instruction2°C to 8°C
- UNSPSC12352203